During the past decade, Yokohama City University Hospital conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 25 clinical trials were completed, i.e. on average, 54.3% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 22 clinical trials were completed. i.e. 95.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yokohama City University Hospital" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Gilead Sciences" with 5 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Mitsubishi Tanabe Pharma America Inc." with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yokohama City University Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Australian and New Zealand Intensive Care Research Centre" with 1 trials as a collaborator, "Berry Consultants" with 1 trials as a collaborator and "Daiichi Sankyo, Inc." with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Yokohama City University Hospital" are "Psoriasis" (6 trials), "Nonalcoholic Steatohepatitis" (4 trials), "ALS" (2 trials), "Juvenile Idiopathic Arthritis" (2 trials) and "Myelodysplastic Syndrome" (2 trials). Many other conditions were trialed in "Yokohama City University Hospital" in a lesser frequency.

Most popular intervention types in "Yokohama City University Hospital" are "Drug" (45 trials), "Biological" (4 trials), "Device" (4 trials), "Other" (4 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Baricitinib" (4 trials), "Apremilast" (3 trials), "BMS-986165" (3 trials) and "MT-1186" (3 trials). Other intervention names were less common.

The vast majority of trials in "Yokohama City University Hospital" are 51 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Yokohama City University Hospital". undefined are not yet recruiting, 14 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Yokohama City University Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Yokohama City University Hospital, 2 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".